» Articles » PMID: 38566834

Work Participation and the COVID-19 Pandemic: an Observational Study in People with Inflammatory Rheumatic Diseases and Population Controls

Overview
Specialty Rheumatology
Date 2024 Apr 3
PMID 38566834
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: During the coronavirus disease 2019 (COVID-19) crisis, people with inflammatory rheumatic diseases (iRDs) might have been more vulnerable for adverse work outcomes (AWOs) and restrictions in work ability and work performance. Our objectives were to compare AWOs during the pandemic and current work ability between iRD patients and controls, understand which patients are most vulnerable for these outcomes and (3) explore the role of work characteristics on work performance while working remotely.

Methods: Patients and population controls in a Dutch COVID-19 cohort study provided information in March 2022 on work participation in March 2020 (pre-pandemic, retrospective) and March 2022 (current). AWOs comprised withdrawal from paid work, working hours reduction or long-term sick leave. Multivariable logistic/linear regression analyses compared outcomes (AWOs/work ability) between groups (patients/controls) and within patients.

Results: Of the pre-pandemic working participants, 227/977 (23%) patients and 79/430 (18%) controls experienced AWOs following pandemic onset. A minority of AWOs (15%) were attributed to COVID-19. Patients were more likely to experience any-cause AWOs (odds ratio range 1.63-3.34) but not COVID-related AWOs, with female patients and patients with comorbidities or physically demanding jobs being most vulnerable. Current work ability was lower in female patients compared with controls [β = -0.66 (95% CI -0.92 to -0.40)]. In both groups, when working remotely, care for children and absence of colleagues had varying effects on work performance (positive 19% and 24%, negative 34% and 57%, respectively), while employer support and reduced commuting had mainly positive effects (83% and 86%, respectively).

Conclusion: During the pandemic, people with iRDs remained at increased risk of AWOs. COVID-related AWOs, however, were infrequent.

Citing Articles

Reference intervals of work ability and productivity loss and their use in patients with inflammatory rheumatic and musculoskeletal diseases.

Capelusnik D, Smeets W, Webers C, Ramiro S, Nikiphorou E, Braekers R RMD Open. 2025; 11(1.

PMID: 39762121 PMC: 11749610. DOI: 10.1136/rmdopen-2024-004877.


A Mixed-Methods Process Evaluation of the Maastricht Work-Related Support Intervention for Healthcare Professionals in Clinical Care.

Butink M, Boonen A, Boymans T, Baadjou V, Hazelzet E, de Rijk A J Occup Rehabil. 2024; .

PMID: 38856951 DOI: 10.1007/s10926-024-10211-0.

References
1.
Boekel L, Hooijberg F, Vogelzang E, Klarenbeek P, Bos W, Tas S . Spinning straw into gold: description of a disruptive rheumatology research platform inspired by the COVID-19 pandemic. Arthritis Res Ther. 2021; 23(1):207. PMC: 8338203. DOI: 10.1186/s13075-021-02574-z. View

2.
Boekel L, Steenhuis M, Hooijberg F, Besten Y, van Kempen Z, Kummer L . Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies. Lancet Rheumatol. 2021; 3(11):e778-e788. PMC: 8346242. DOI: 10.1016/S2665-9913(21)00222-8. View

3.
Hooijberg F, Boekel L, Vogelzang E, Leeuw M, Boers M, van Vollenhoven R . Patients with rheumatic diseases adhere to COVID-19 isolation measures more strictly than the general population. Lancet Rheumatol. 2020; 2(10):e583-e585. PMC: 7579459. DOI: 10.1016/S2665-9913(20)30286-1. View

4.
Hausmann J, Kennedy K, Simard J, Liew J, Sparks J, Moni T . Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. Lancet Rheumatol. 2021; 3(10):e707-e714. PMC: 8298011. DOI: 10.1016/S2665-9913(21)00175-2. View

5.
Boekel L, Stalman E, Wieske L, Hooijberg F, van Dam K, Besten Y . Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies. Lancet Rheumatol. 2022; 4(6):e417-e429. PMC: 9054068. DOI: 10.1016/S2665-9913(22)00102-3. View